<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-108019</identifier>
<setSpec>0214-1582</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">48th Annual Meeting of the American Society of Clinical Oncology: Novel findings in breast cancer</dc:title>
<dc:description xml:lang="en">The most important world congress on cancer is the Annual Meeting of the American Society of Clinical Oncology (ASCO), where the most notable findings in the distinct fields of oncology are presented. This year, the main novelty in breast cancer was related to the first line treatment of metastatic HER2 disease with the development of pertuzumab. This article summarizes the innovations presented in the field of breast carcinoma(AU)</dc:description>
<dc:creator>Fernández Pérez, Yolanda</dc:creator>
<dc:creator>Sampedro Gimeno, Teresa</dc:creator>
<dc:creator>Luque Cabal, María</dc:creator>
<dc:creator>Peláez Fernández, Ignacio</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El congreso más importante a nivel mundial sobre cáncer es el de la American Society of Clinical Oncology, que tiene carácter anual y en el que se presentan las novedades más relevantes en los diferentes campos de la Oncología. Respecto al cáncer de mama, la principal novedad ha sido en la primera línea de tratamiento en pacientes HER2 con la llegada del pertuzumab. A continuación, resumimos lo más destacado que se ha presentado en relación con el cáncer de mama(AU)</dc:description>
<dc:source>Rev. senol. patol. mamar. (Ed. impr.);25(4): 147-151, oct.-dic. 2012.</dc:source>
<dc:identifier>ibc-108019</dc:identifier>
<dc:title xml:lang="es">48th Annual Meeting of the American Society of Clinical Oncology: aspectos relevantes en cáncer de mama</dc:title>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d1968^s22080</dc:subject>
<dc:subject>^d33861^s22066</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d29627</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d13339^s22048</dc:subject>
<dc:subject>^d13339^s22049</dc:subject>
<dc:subject>^d1968^s22054</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d913^s22073</dc:subject>
<dc:subject>^d23628^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
